XOMA - NASDAQ
XOMA Royalty Corp.
$41.92
+0.55%XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
At a Glance
Live SnapshotXOMA Royalty Corp. Management Team
Mr. Owen P. Hughes Jr.
Chief Executive Officer & Director
Compensation
$1,000,126
Mr. Bradley Sitko
Chief Investment Officer
Compensation
$788,900
Mr. Thomas M. Burns
Senior Vice President of Finance & Chief Financial Officer
Compensation
$674,186
XOMA Royalty Corp. Insider Positioning
During the last 12 months, insiders have purchased $2.56M and sold $552 worth of XOMA shares, resulting in $2.56M of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
100.0K
2.50M
15
552.00
+2.5M
+$2.50M
9-12 Months
2.0K
50.78K
0
0.00
+51K
+$51K
Top Buyers
Hughes Owen
Director, Officer: Chief Executive Officer
$2.50M
Sitko Bradley
Officer: Chief Investment Officer
$51K
Top Sellers
Burns Thomas M.
Officer: Svp, Finance & Cfo
$552
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $2.56M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
2 insider buyers vs. 1 sellers. More insiders buying than selling indicates positive sentiment.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
XOMA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | March 30, 2026 | May 21, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 15, 2025 | May 21, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 02, 2024 | May 15, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 04, 2023 | April 04, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 07, 2022 | May 18, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 08, 2021 | May 19, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 09, 2020 | May 20, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 05, 2019 | May 16, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 03, 2018 | May 17, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 05, 2017 | May 18, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.